Safety of Hydroxychloroquine: What a Dermatologist Should Know
- PMID: 39899183
- PMCID: PMC11850461
- DOI: 10.1007/s40257-025-00919-x
Safety of Hydroxychloroquine: What a Dermatologist Should Know
Abstract
The unique immunomodulatory properties of hydroxychloroquine (HCQ) have attracted considerable interest beyond its use for malaria and rheumatological diseases, including a variety of dermatological conditions. Over recent years, especially after the coronavirus disease 2019 (COVID-19) pandemic, the prescription of HCQ has also significantly expanded, sometimes inappropriately, thus posing additional challenges on its optimal use, due to emerging safety issues. In this review, we provide dermatologists with the latest advancements on selected clinically relevant toxicities, namely retinopathy, pro-arrhythmia, cutaneous reactions, and neuropsychiatric effects. It is hoped this update can assist dermatologists to identify high-risk patients for tailored monitoring, screening, and risk minimization strategies, thus supporting safer HCQ prescribing.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Funding: Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement. Authors' Contributions: All authors participated equally in the drafting of the manuscript. All authors read and approved the final paper. Conflict of Interest: All authors have no relevant financial or non-financial interests to disclose. Ethics Approval; Patient Consent: Not applicable. Code Availability: Not applicable. Data availability: Not applicable.
Figures

Similar articles
-
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.Trials. 2020 Jul 2;21(1):607. doi: 10.1186/s13063-020-04557-y. Trials. 2020. PMID: 32616063 Free PMC article.
-
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4. Trials. 2020. PMID: 32493478 Free PMC article.
-
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.Pain Physician. 2020 Aug;23(4S):S351-S366. Pain Physician. 2020. PMID: 32942793 Review.
-
Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.Immun Inflamm Dis. 2021 Mar;9(1):31-36. doi: 10.1002/iid3.374. Epub 2020 Nov 26. Immun Inflamm Dis. 2021. PMID: 33244901 Free PMC article.
-
Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.Clin Toxicol (Phila). 2021 Jan;59(1):12-23. doi: 10.1080/15563650.2020.1817479. Epub 2020 Sep 22. Clin Toxicol (Phila). 2021. PMID: 32960100 Review.
Cited by
-
Cutaneous Adverse Effects of Hydroxychloroquine and Leflunomide in Connective Tissue Diseases: A Report of Three Cases and a Literature Review.Cureus. 2025 Jun 7;17(6):e85495. doi: 10.7759/cureus.85495. eCollection 2025 Jun. Cureus. 2025. PMID: 40625496 Free PMC article.
References
-
- Stokkermans TJ, Falkowitz DM, Trichonas G. Chloroquine and Hydroxychloroquine Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Sep 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537086/. Accessed 8 Sep 2024 - PubMed
-
- US prescribing information: Plaquenil [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/009768s054lbl.pdf. Accessed 8 Sep 2024
-
- go.drugbank.com: Hydroxychloroquine. [Internet]. [cited 2024 Sep 8]. Available from: https://go.drugbank.com/drugs/DB01611. Accessed 8 Sep 2024
-
- Paludetto MN, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 2023;51(3):293–305. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical